编者按：2024年欧洲肿瘤内科学会（ESMO）年会将于9月13日～17日在西班牙巴塞罗那召开。目前，ESMO官网已公布报告标题及壁报标题，《肿瘤瞭望》特将肺癌部分的口头报告进行汇总，如有缺漏和错误，欢迎留言指正。

 

摘要号：LBA8

英文标题：Precision Immuno-Oncology for advanced Non-small cell lung cancer(NSCLC)patients with PD-(L)1 inhibitors Resistance(PIONeeR):a phase Ib/IIa clinical trial targeting identified resistance pathways

中文标题：关于晚期非小细胞肺癌（NSCLC）患者对PD-(L)1抑制剂耐药的精准免疫肿瘤学：一项针对已识别耐药通路的Ib/IIa期临床试验（PIONeeR）

讲者：Pascale Tomasini

 

 

摘要号：LBA48

英文标题：CCTG BR.31:A global，double-blind placebo-controlled，randomized phase III study of adjuvant durvalumab in completely resected non-small-cell lung cancer(NSCLC)

中文标题：CCTG BR.31：度伐利尤单抗辅助治疗完全切除NSCLC的全球、双盲、安慰剂对照、随机III期研究

讲者：Glenwood Goss

 

摘要号：LBA52

英文标题：Interim Analysis of GALAXIES Lung-201:Phase 2，Randomized，Open-label Platform Study of Belrestotug Plus Dostarlimab in Patients(pts)With Previously Untreated Locally Advanced/Metastatic(LA/M)PD-L1 High(TPS>/=50%)Non-Small Cell Lung Cancer(NSCLC)

中文标题：II期随机、开放标签平台研究GALAXIES Lung-201中期分析：Belrestotug联合Dostarlimab治疗初治局部晚期/转移性、PD-L1高表达（TPS≥50%）的NSCLC患者

讲者：David R Spigel

 

摘要号：LBA53

英文标题：Nivolumab(NIVO)plus relatlimab with platinum-doublet chemotherapy(PDCT)vs NIVO+PDCT as first-line(1L)treatment(tx)for stage IV or recurrent NSCLC:results from the randomized phase 2 RELATIVITY-104 study

中文标题：纳武利尤单抗+Relatlimab联合铂类双药化疗vs纳武利尤单抗+铂类双药化疗作为IV期或复发性NSCLC的一线治疗的随机II期RELATIVITY-104研究结果

讲者：Nicolas Girard

 

摘要号：LBA54

英文标题：Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutated，Advanced Non-small Cell Lung Cancer After Disease Progression on Osimertinib:2nd Interim Overall Survival From MARIPOSA-2

中文标题：埃万妥单抗联合化疗vs化疗用于奥希替尼治疗后疾病进展的EGFR突变晚期NSCLC：MARIPOSA-2试验第2次中期总生存（OS）分析

讲者：Sanjay Popat

 

摘要号：LBA55

英文标题：Mechanisms of Acquired Resistance to First-line Amivantamab Plus Lazertinib Versus Osimertinib in Patients With EGFR-mutant Advanced Non-Small Cell Lung Cancer:An Early Analysis from the Phase 3 MARIPOSA Study

中文标题：埃万妥单抗+拉泽替尼vs.奥希替尼一线治疗EGFR突变晚期非小细胞肺癌患者的获得性耐药机制：一项来自Ⅲ期MARIPOSA研究的早期分析

讲者：Benjamin Besse

 

摘要号：LBA81

英文标题：Durvalumab(D)as consolidation therapy in limited-stage SCLC(LS-SCLC):outcomes by prior concurrent chemoradiotherapy(cCRT)regimen and prophylactic cranial irradiation(PCI)use in the ADRIATIC trial

中文标题：度伐利尤单抗巩固治疗局限期小细胞肺癌（SCLC）：ADRIATIC试验中根据既往接受的同步放化疗（cCRT）方案和预防性颅脑照射（PCI）使用状态分析的结果

讲者：Suresh Senan

 

摘要号：LBA83

英文标题：PECATI:A phase 2 trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

中文标题：评估仑伐替尼联合帕博利珠单抗用于经治晚期B3胸腺瘤和胸腺癌的疗效和安全性的II期PECATI试验

讲者：Jordi Remon Masip

 

摘要号：608O

英文标题：Preliminary safety and clinical activity of ASP3082，a first-in-class，KRAS G12D selective protein degrader in adults with advanced pancreatic(PC)，colorectal(CRC)，and non-small cell lung cancer(NSCLC)

中文标题：首创KRAS G12D选择性蛋白降解剂ASP3082在晚期胰腺癌、结直肠癌和NSCLC成人患者中的初步安全性和临床活性

讲者：Wungki Park

 

摘要号：1253O

英文标题：Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive(ALK+)solid tumors

中文标题：NVL-655治疗ALK阳性实体瘤的I/II期ALKOVE-1研究

讲者：Alexander E.Drilon

 

摘要号：1786O

英文标题：BMS-986012(anti-fucosyl-monosialoganglioside-1[fuc-GM1])with carboplatin+etoposide+nivolumab(CE/NIVO)as first-line(1L)therapy in extensive-stage small cell lung cancer(ES-SCLC):interim analysis(IA)of a randomized phase 2 study

中文标题：BMS-986012[抗岩藻糖基单唾液酸神经节苷脂-1（fuc-GM1）]联合卡铂+依托泊苷+纳武利尤单抗作为广泛期小细胞肺癌一线治疗：一项随机II期研究的中期分析

讲者：Ewa Kalinka

 

 

摘要号：LBA49

英文标题：Associations of ctDNA clearance(CL)during neoadjuvant Tx with pathological response and event-free survival(EFS)in pts with resectable NSCLC(R-NSCLC):expanded analyses from AEGEAN

中文标题：可切除NSCLC患者新辅助治疗期间ctDNA清除率与病理缓解和无事件生存期（EFS）的关系：AEGEAN的扩展分析

讲者：Martin Reck

 

摘要号：LBA50

英文标题：Perioperative nivolumab(NIVO)v placebo(PBO)in patients(pts)with resectable NSCLC:clinical update from the phase 3 CheckMate 77T study

中文标题：对比纳武利尤单抗vs安慰剂用于可切除NSCLC患者的围手术期治疗：III期CheckMate 77T研究的临床更新

讲者：Jonathan D.Spicer

 

摘要号：LBA51

英文标题：Circulating tumor DNA(ctDNA)dynamics and treatment responses in chemotherapy-ineligible patients(pts)with unresectable Stage III NSCLC from the phase 2 DUART trial

中文标题：II期DUART试验中不适合化疗的无法切除III期NSCLC患者ctDNA动力学和治疗缓解

讲者：Andrea Riccardo Filippi

摘要号：LBA56

英文标题：Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC(mNSCLC)

中文标题：恩考芬尼联合比美替尼治疗BRAF V600E突变转移性NSCLC患者的II期PHAROS研究的最新疗效和安全性

讲者：Gregory J.Riely

 

摘要号：LBA57

英文标题：Adagrasib(ADA)vs docetaxel(DOCE)in patients(pts)with KRASG12C-mutated advanced NSCLC and baseline brain metastases(BM):results from KRYSTAL-12

中文标题：对比Adagrasib vs多西他赛在患有KRAS G12C突变晚期NSCLC、基线脑转移的患者中的疗效：KRYSTAL-12的结果

讲者：Fabrice Barlesi

 

摘要号：1206MO

英文标题：ALINA:exploratory biomarker analyses in patients(pts)with resected ALK+non-small cell lung cancer(NSCLC)treated with adjuvant alectinib vs chemotherapy(chemo)

中文标题：ALINA试验中阿来替尼vs.化疗辅助治疗可切除ALK+非小细胞肺癌患者的探索性生物标志物分析

讲者：Ben J.Solomon

 

摘要号：1207MO

英文标题：Neoadjuvant nivolumab monotherapy for high-risk clinical stage I non-small cell lung cancer:A phase 2 POTENTIAL study

中文标题：纳武利尤单抗单药用于高危临床Ⅰ期非小细胞肺癌的新辅助治疗：一项Ⅱ期POTENTIAL研究

讲者：Yasuhiro Tsutani

 

摘要号：1208MO

英文标题：Phase III trial of perioperative pirfenidone therapy for lung cancer with idiopathic pulmonary fibrosis(IPF):NEJ034 study

中文标题：围手术期吡非尼酮用于发生特发性肺纤维化（IPF）的肺癌患者：Ⅲ期NEJ034研究

讲者：Yukinobu Goto

 

摘要号：1209MO

英文标题：Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer:Combined analysis of 5-year outcomes from NEOSTAR and CA209-159

中文标题：纳武利尤单抗vs纳武利尤单抗+伊匹木单抗用于可切除NSCLC新辅助治疗：NEOSTAR和CA209-159试验5年结果综合分析

讲者：Joshua Reuss

 

摘要号：1240MO

英文标题：Quantitative radiomics for the detection of symptomatic pneumonitis following chemoradiotherapy in patients with Stage III unresectable NSCLC

中文标题：定量放射组学检测III期不可切除NSCLC患者放化疗后出现的症状性肺炎

讲者：Jarushka Naidoo

 

摘要号：1241MO

英文标题：Osimertinib(osi)after definitive chemoradiotherapy(CRT)in unresectable(UR)stg III EGFRm NSCLC:Analyses of CNS and distant progression from the Phase 3 LAURA study

中文标题：根治性放化疗后采用奥希替尼治疗不可切除Ⅲ期EGFR突变NSCLC：Ⅲ期LAURA试验中CNS和远处进展分析

讲者：陆舜教授丨上海交通大学附属胸科医院

 

摘要号：1242MO

英文标题：The addition of belomethason propionate inhalation to radical radiotherapy for patients with locally advanced non-small cell lung cancer:a randomized controlled，open-label phase II study

中文标题：局部晚期NSCLC患者在根治性放疗基础上加用丙酸倍氯米松吸入剂：一项随机对照、开放标签II期研究

讲者：张杰丨上海交通大学附属胸科医院

摘要号：1243MO

英文标题：A phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin for concurrent chemoradiotherapy in elderly patients(≥75 years)with unresectable locally advanced NSCLC:JCOG1914

中文标题：比较每周卡铂联合白蛋白紫杉醇vs每日低剂量卡铂用于不可切除局部晚期NSCLC老年患者（≥75岁）的同步放化疗：Ⅲ期JCOG1914研究

讲者：Shota Omori

 

摘要号：1254MO

英文标题：Safety and Antitumor Activity of Zipalertinib in NSCLC Patients(pts)with EGFR Exon 20 Insertion(ex20ins)Mutations Who Received Prior Amivantamab

中文标题：Zipalertinib在既往接受过埃万妥单抗治疗的EGFR 20外显子插入突变NSCLC患者中的安全性和抗肿瘤活性

讲者：Antonio Passaro

 

摘要号：1255MO

英文标题：A Phase II Safety and Efficacy Study of PM8002/BNT-327 in Combination with Chemotherapy in Patients with EGFR-mutated Non-Small Cell Lung Cancer(NSCLC)

中文标题：PM8002/BNT-327联合化疗治疗EGFR突变NSCLC患者的安全性和疗效的Ⅱ期研究结果

讲者：吴一龙教授丨广东省人民医院

 

摘要号：1256MO

英文标题：Phase 1/2 ARROS-1 study of zidesamtinib(NVL-520)in ROS1 fusion-positive solid tumors

中文标题：评估Zidesamtinib(NVL-520)治疗ROS1融合阳性实体瘤的Ⅰ/Ⅱ期ARROS-1研究

讲者：Benjamin Besse

 

摘要号：1257MO

英文标题：ABBV-400，a c-Met Protein–Targeting Antibody-Drug Conjugate(ADC)，in Patients(Pts)With Advanced EGFR Wildtype(WT)Non-Squamous(NSQ)Non-Small Cell Lung Cancer(NSCLC):Results From a Phase 1 Study

中文标题：靶向c-Met蛋白的抗体药物偶联物（ADC）ABBV-400治疗晚期EGFR野生型非鳞NSCLC的Ⅰ期研究的结果

讲者：María De Miguel

 

摘要号：1258MO

英文标题：Low dose versus standard dose pembrolizumab for treatment of stage 4 stage non-small cell lung carcinoma:Results of the pre-planned interim analysis of the NVALT-30 clinical trial

中文标题：低剂量vs.标准剂量帕博利珠单抗治疗Ⅳ期非小细胞肺癌：NVALT-30临床试验预先计划中期分析的结果

讲者：Michel Van den Heuvel

 

摘要号：1259MO

英文标题：Encorafenib plus binimetinib in patients(pts)with previously untreated BRAF V600E-mutant advanced Non-Small Cell Lung Cancer(NSCLC):an open-label，multicenter phase 2 trial(IFCT-1904 ENCO-BRAF)

中文标题：恩考芬尼联合比美替尼治疗初治BRAF V600E突变晚期NSCLC患者：开放标签、多中心Ⅱ期IFCT-1904 ENCO-BRAF试验

讲者：David Planchard

摘要号：1910MO

英文标题：ARTIMES:Automated Response evaluation to Treatment In MESothelioma

中文标题：ARTIMES：间皮瘤治疗疗效的自动评估

讲者：Kevin B.Groot Lipman